Delivery systems for immunomodulatory proteins and peptides

被引:12
作者
Anderson, PM
机构
[1] Dept. of Pediat. and Adol. Medicine, Mayo Clinic, Rochester, MN
[2] Dept. of Paediatr. and Adol. Med., Mayo Clinic, Rochester, MN 55905, East 9
关键词
D O I
10.2165/00063030-199707010-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polypeptide and protein immunomodulators are subject to absorption, biodistribution, metabolism and degradation at sites and rates which may not permit effective interactions with components of the immune system. Drug carrier technology can overcome some of these obstacles. Because of the lipid and particulate nature of liposomes, increased delivery of immunomodulators to lymphatics, lymph nodes, lymphatic organs and concentrations of macrophages is possible when an immunomodulator is associated with a liposome. Interleukin-2 (IL-2) liposomes have been shown to have less toxicity and increased immunotherapeutic effects in a number of model systems and are currently in human clinical trials. Local routes such as aerosol delivery to the lung are particularly well suited to use with liposomes containing immunomodulators. Polypeptides can also enhance the interaction of an immunomodulator with the immune system via increased immunostimulation; this can provide a means to enhance oral delivery and to achieve depot effects. Polysaccharide microspheres have been shown to be effective biodegradable carriers of immunomodulators. Finally, genetically engineered bacteria, viruses and mammalian cells may function as delivery systems for immunomodulatory peptides and proteins. Attenuated Salmonella strains can deliver immunomodulators to the gut-associated lymphoid tissue, liver and spleen. In mouse experiments using tumour cells producing granulocyte-macrophage colony-stimulating factor (GM-CSF), irradiated tumour preparations produced GM-CSF and were capable of eliciting effective cell-mediated immune responses, including destruction and elimination of tumour as well as resistance to tumour challenge (i.e. memory response). A wide variety of immunomodulators have been tested using this strategy; IL-2 and GMCSF are among the most potent inducers of both cell-mediated effector and memory responses. In summary, use of delivery systems can significantly enhance the immunomodulatory potential of polypeptides and proteins.
引用
收藏
页码:51 / 65
页数:15
相关论文
共 90 条
[31]  
GANSBACHER B, 1990, CANCER RES, V50, P7820
[32]   INTERLEUKIN-2 GENE-TRANSFER INTO TUMOR-CELLS ABROGATES TUMORIGENICITY AND INDUCES PROTECTIVE IMMUNITY [J].
GANSBACHER, B ;
ZIER, K ;
DANIELS, B ;
CRONIN, K ;
BANNERJI, R ;
GILBOA, E .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (04) :1217-1224
[33]   CHARACTERIZATION AND ADMINISTRATION OF CYCLOSPORINE LIPOSOMES AS A SMALL-PARTICLE AEROSOL [J].
GILBERT, BE ;
WILSON, SZ ;
GARCON, NM ;
WYDE, PR ;
KNIGHT, V .
TRANSPLANTATION, 1993, 56 (04) :974-977
[34]   In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide [J].
Goldbach, P ;
Dumont, S ;
Kessler, R ;
Poindron, P ;
Stamm, A .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1996, 270 (03) :L429-L434
[35]  
GOLUMBEK PT, 1993, CANCER RES, V53, P5841
[36]   TREATMENT OF ESTABLISHED RENAL-CANCER BY TUMOR-CELLS ENGINEERED TO SECRETE INTERLEUKIN-4 [J].
GOLUMBEK, PT ;
LAZENBY, AJ ;
LEVITSKY, HI ;
JAFFEE, LM ;
KARASUYAMA, H ;
BAKER, M ;
PARDOLL, DM .
SCIENCE, 1991, 254 (5032) :713-716
[37]  
GOOD MF, 1988, J IMMUNOL, V141, P972
[38]   THE INFLUENCE OF BRANCHED POLYPEPTIDE CARRIERS ON THE IMMUNOGENICITY OF PREDICTED EPITOPES OF HSV-1 GLYCOPROTEIN-D [J].
HILBERT, A ;
HUDECZ, F ;
MEZO, G ;
MUCSI, I ;
KAJTAR, J ;
KURUCZ, I ;
RAJNAVOLGYI, E ;
GERGELY, J .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1994, 40 (06) :609-617
[39]   LIPOSOME-FORMULATED INTERLEUKIN-2 AS AN ADJUVANT OF RECOMBINANT HSV GLYCOPROTEIN GD FOR THE TREATMENT OF RECURRENT GENITAL HSV-2 IN GUINEA-PIGS [J].
HO, RJY ;
BURKE, RL ;
MERIGAN, TC .
VACCINE, 1992, 10 (04) :209-213
[40]   INTERLEUKIN-7 INDUCES CD4+ T-CELL-DEPENDENT TUMOR REJECTION [J].
HOCK, H ;
DORSCH, M ;
DIAMANTSTEIN, T ;
BLANKENSTEIN, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1291-1298